Combination immunotherapy drugs herald new hope for melanoma patients with long term survival rates

A combination of two immunotherapy drugs, ipilimumab and nivolumab, has stopped or reversed the progression of advanced melanoma for five years or more in one in two patients, according to a study led by The Royal Marsden NHS Foundation Trust.